Remove 2019 Remove Pharmaceutical Companies Remove Vaccines
article thumbnail

Next Generation RNA Therapeutics and Vaccines – A Marvel of The Lifesciences Industry

Roots Analysis

The next generation RNA therapeutics and RNA vaccines pipeline currently features the presence of more than 20 circular RNA therapeutics and vaccines, being developed across initial stages of drug development (discovery and preclinical).

article thumbnail

The future of RNA-based Therapeutics  and Vaccines: Introducing advanced, Unrivalled Treatment Approaches

Roots Analysis

In this context, several industry players have demonstrated high inclination towards supporting and advancing the development of next generation RNA-based therapeutics, vaccine and technologies. The below given figure provides an illustrative summary of the benefits of next generation RNA-based vaccines and RNA-based therapeutics market.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pfizer: Pharma needs a business strategy for a digital world

pharmaphorum

Its chief digital and technology officer Lidia Fonseca offered a fascinating insight into how one biggest pharmaceutical companies – and one of those most closely associated with the pandemic (alongside the likes of BioNTech, Moderna and AstraZeneca) – has been transforming itself. Digital fluency and change.

article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.

article thumbnail

Pharma sector reels as UK Government doubles VPAS payback rate on NHS drugs

Pharmaceutical Technology

For 2019–23, this was capped at 2% per year. During 2019–21, when sales being close to predicted levels resulted in single-digit payback rates, the scheme was relatively popular with the pharma sector. At this punitive percentage, VPAS member companies may be required to pay back up to GBP3.3 billion ($4.1 billion) to the NHS.

article thumbnail

Three pillars of post-pandemic launch excellence

pharmaphorum

Even with the vaccine roll-out, further waves of COVID infection and lockdowns mean these vital drivers of launch performance remain impacted in 2021, and even beyond. This wasn’t the case in Germany, where a resilient system meant that productivity in terms of HTA decisions was higher in 2020 than the historic average from 2015-2019.

article thumbnail

NK cell immunotherapy: what’s next in clinical development?

European Pharmaceutical Review

Pharmaceutical companies such as Sanofi and AstraZeneca are currently conducting several high-potential clinical development programmes in oncology in collaboration with Innate Pharma. Innate Pharma has also partnered with Takeda to develop an antibody drug conjugate (ADC). percent, reaching even 57.1 percent in the skin.